• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

LASIK Xtra gets CE approval

Article

Avedro Inc.’s proprietary LASIK Xtra procedure has received CE mark approval. LASIK Xtra is a 2-minute corneal crosslinking procedure used in conjunction with standard LASIK to restore the biomechanical integrity and strength to the cornea after a LASIK procedure.

Waltham, MA-Avedro Inc.’s proprietary LASIK Xtra procedure has received CE mark approval. LASIK Xtra is a 2-minute corneal crosslinking procedure used in conjunction with standard LASIK to restore the biomechanical integrity and strength to the cornea after a LASIK procedure.

LASIK Xtra has been successfully used in thousands of LASIK surgeries outside the United States.

“Crosslinking within a LASIK procedure using LASIK Xtra is simple, fast and safe,” said A. John Kanellopoulos, MD, a member of Avedro’s medical advisory board. “In studies we’ll be reporting at ASCRS in April, we’ve found that after almost 2 years of follow-up, [patients with hyperopia] appear to have a completely different clinical course if we employ prophylactic crosslinking in their LASIK procedures. Hyperopic LASIK typically regresses more than myopic LASIK.”

LASIK Xtra combines riboflavin ophthalmic solution (VibeX) with its UVA irradiation system (KXL System) to achieve accelerated corneal crosslinking during a LASIK procedure.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.